Document is current
Any future updates will be listed below
-
Authors
Palová, Lenka
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04234113 at ClinicalTrials.govnct04234113 at ClinicalTrials.govDocuments that mention this clinical trial
563 Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys
https://doi.org/10.1136/jitc-2020-sitc2020.0563
713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers
https://doi.org/10.1136/jitc-2023-sitc2023.0713
484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.484
716 AURELIO-04: a phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors
https://doi.org/10.1136/jitc-2022-sitc2022.0716
502 Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.502
807 A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0807
510 SO-C101, a high-affinity IL-15Rbg agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations
https://doi.org/10.1136/jitc-2021-sitc2021.510
Documents that mention this clinical trial
563 Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys
https://doi.org/10.1136/jitc-2020-sitc2020.0563
713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers
https://doi.org/10.1136/jitc-2023-sitc2023.0713
484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.484
716 AURELIO-04: a phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors
https://doi.org/10.1136/jitc-2022-sitc2022.0716
502 Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.502
807 A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0807
510 SO-C101, a high-affinity IL-15Rbg agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations
https://doi.org/10.1136/jitc-2021-sitc2021.510
